Skip to main content

Table 9 Cochrane review all-cause mortality results

From: A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Intervention

Comparator

Risk ratio (M-H, fixed, 95% CI)

Detemir

NPH

4.97 [0.79, 31.38] 

Glargine

NPH

0.14 [0.00, 6.98] 

Detemir

Glargine

No deaths

Degludec

Detemir

No deaths

Degludec

Glargine

1.34 [0.15, 11.93] (combined)

  1. Reported values are for adult subgroup analysis. Where this subgroup analysis was not available, the analysis group is indicated in parentheses.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us